Pandorum Technologies

Pandorum Technologies is a private, preclinical-stage biotech firm founded in 2011 and based in San Francisco, operating at the intersection of tissue engineering and regenerative medicine. Its core technology platform integrates bio-materials, cellular engineering, exosome/nanotherapy, and bio-fabrication techniques to build functional human tissues. The company's pipeline is led by a bio-engineered cornea product aimed at treating corneal disorders, supported by a mini-liver platform for drug discovery and an early-stage lung regeneration program. Pandorum is approaching clinical-stage development and has gained recognition in startup competitions and media lists.

Integrated platform combining bio-engineered ECM materials, scalable MSC culture, exosome/nanotherapy production, and bio-fabrication (e.g., 3D printing) to build functional human tissues and cell-free therapies.

Pandorum competes in corneal regeneration with companies like Eyegenix, Aurion Biotech, and numerous academic centers. In the organoid space, it faces competition from Hubrecht Organoid Technology, STEMCELL Technologies, and other biotechs. The exosome therapy field is crowded with players like Codiak BioSciences, Evox Therapeutics, and many others, all targeting regenerative applications.